Intraspinal techniques for pain management in cancer patients: a systematic review

Myers, Jeff; Chan, Vincent; Jarvis, Virginia; Walker-Dilks, Cindy

doi:10.1007/s00520-009-0784-2

Cited by 46 publications

(29 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 2010, Meyers and co-workers performed a systematic review, finding 12 randomized controlled trials (RCT) about intraspinal analgesia for cancer pain [166]. Seven out of 12 studies evaluated the effect of epidural analgesia, and hence only five were concerned with ITA.…”

Section: Intrathecal Analgesia In Cancer Painmentioning

confidence: 99%

See 1 more Smart Citation

The Cerebrospinal Fluid in Severe Pain Conditions : Clinical, Pharmacological and Proteomic Aspects

Bäckryd¹

2015

View full text Add to dashboard Cite

The treatment of both cancer pain and non-cancer chronic pain is still suboptimal. The overall aim of this PhD thesis was to conduct translational pain research at the interface between clinical pain medicine and the field of human proteomics, using the practice of intrathecal analgesia at our institution as a starting point. Hence, the cerebrospinal fluid (CSF) is at the centre of the present dissertation, both as a target for infusing analgesics (Papers I and II – clinical and pharmacological aspects) and as an important biofluid for human biomarker studies (Papers III and IV – proteomic aspects). In Paper I, 28 cases of intrathecal analgesia in cancer patients were prospectively followed. Movement-evoked breakthrough pain remained a major clinical problem throughout the study month despite otherwise successful intrathecal analgesia (defined as good control of spontaneous resting pain paralleled by a marked decrease of concomitant systemic opioid doses). This study therefore illustrates the importance of considering not only spontaneous resting pain but also movement-evoked breakthrough pain. In Paper II, an expert-based algorithm for trialing the intrathecal analgesic ziconotide by bolus injections was evaluated in an open-label study of 23 patients with chronic neuropathic pain. We found few responders (13%) according to the strict criteria of the algorithm, but ziconotide bolus injection trialing seems feasible. The predictive power of ziconotide bolus trialing remains unclear, and the pharmacological profile of ziconotide (with very slow tissue penetration due to high hydrophilicity) calls the rationale for ziconotide bolus trialing into question. In Paper III, we found low levels of beta-endorphin in the CSF of chronic neuropathic pain patients (n=15) compared to healthy controls (n=19). We speculate that this might indicate dysfunctional top-down control of nociception. Substance P levels in the CSF did not differ by univariate statistics. In Paper IV, the CSF proteome of 11 patients with chronic neuropathic pain and 11 healthy controls was exploratively studied, combining gel-based proteomics with multivariate data analysis. After eliminating four proteins associated with age, 32 proteins were found to highly discriminate between groups. Among these, the seven proteins having the highest discriminatory power between patients and controls were: one isoform of angiotensinogen, two isoforms of alpha-1-antitrypsin, three isoforms of haptoglobin, and one isoform of pigment epithelium-derived factor. In conclusion, this PhD thesis demonstrates the fruitfulness of studying the CSF, both as a target for infusing analgesics and as a potential mirror of the neurobiological processes involved in pathological pain conditions. The thesis points to the need for more research into the mechanisms of different pain conditions, in order to hopefully achieve the vision of mechanism-based pain diagnoses

show abstract

Section: Intrathecal Analgesia In Cancer Painmentioning

confidence: 99%

“…Hence, according to the standards of evidence-based medicine, there is a paucity of high-quality studies. However, reviewers in the field seem to agree that ITA is a valuable analgesic technique in intractable cancer-related pain [11,97,166,224].…”

Section: Intrathecal Analgesia In Cancer Painmentioning

confidence: 99%

The Cerebrospinal Fluid in Severe Pain Conditions : Clinical, Pharmacological and Proteomic Aspects

Bäckryd¹

2015

View full text Add to dashboard Cite

show abstract

“…Verfahren zur rückenmarknahen Opioidtherapie sind in der Tumorschmerztherapie heute in den Hintergrund getreten, können im Einzelfall jedoch in therapeutisch komplexen Situationen ein entscheidender Schlüssel zur Schmerzlinderung sein [12].…”

Section: Periduralkatheterunclassified

Tumorschmerz in der Palliativmedizin

et al. 2012

View full text Add to dashboard Cite

During the course of cancer progression up to 90% of the patients suffer from pain of nociceptive, neuropathic or mixed nociceptive/neuropathic origin. Psychological, social or existential factors may additionally affect the intensity of pain (concept of "total pain"). The WHO "analgesic ladder" provides a large variety of effective drugs that can be used according to the specific pain type. Parenteral or peridural opioid therapy as well as neurodestructive methods can effectively support the analgesic treatment in selected cases.

show abstract

“…In the intrathecal route, less than 10% of the systemic dose for equianalgesia is required [9]. Patients with wide spread pain is amenable to this option to address pain in various anatomic locations: head and neck, upper and lower extremities and trunk.…”

Section: Editorialmentioning

confidence: 99%

Untitled

2016

BAOJPM

View full text Add to dashboard Cite

Intraspinal techniques for pain management in cancer patients: a systematic review

Abstract: Intraspinal techniques monitored by an interprofessional health care team should be included as part of a comprehensive cancer pain management program.

Cited by 46 publications

References 32 publications

The Cerebrospinal Fluid in Severe Pain Conditions : Clinical, Pharmacological and Proteomic Aspects

The Cerebrospinal Fluid in Severe Pain Conditions : Clinical, Pharmacological and Proteomic Aspects

Tumorschmerz in der Palliativmedizin

Untitled

Contact Info

Product

Resources

About